Macleods Pharma USA recalls blood pressure medication nationwide

Thousands of bottles of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide tablets are being recalled after failing to meet federal quality standards.

Macleods Pharma USA is recalling certain lots of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Tablets after the medication failed to meet federal quality standards, according to the U.S. Food and Drug Administration (FDA). The FDA listed the reason for the recall as "failed dissolution specifications," meaning the pills did not dissolve as required during testing.

The nationwide recall affects 3,528 30-count bottles from lot 12251163A and 216 90-count bottles from lot 12251163B. The 30-count bottles have NDC 33342-246-07, while the 90-count bottles have NDC 33342-246-10. Both lots have an expiration date of May 31, 2027.

The FDA classified the action as a Class II recall, meaning use of the affected medication may cause temporary or medically reversible adverse health consequences, though the likelihood of serious health consequences is considered remote. Macleods Pharma USA initiated the recall Oct. 7, and the FDA classified it Oct. 26.

Consumers can check their prescription bottles for the lot number and National Drug Code, or NDC. The recall remains ongoing and affects products distributed nationwide.

This recall comes weeks after another blood pressure medication was pulled from shelves over a similar issue. In September, India-based Inventia Healthcare Ltd. recalled 13,567 bottles of 25-milligram chlorthalidone tablets after the medication failed dissolution testing, according to the FDA.

Key facts

  • Macleods Pharma USA is recalling Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Tablets due to failed dissolution specifications.
  • The recall involves two lots with an expiration date of May 31, 2027.
  • The FDA classified the recall as Class II.

Three perspectives

Neutral

Macleods Pharma USA is recalling certain lots of blood pressure medication after the tablets failed to meet federal dissolution standards.

Positive

The FDA has classified the action as a Class II recall, noting that the likelihood of serious health consequences is considered remote.

Negative

The recalled medication may cause temporary or medically reversible adverse health consequences.

Your week in news, every Wednesday

The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.

Choose your news coverage

Please choose and confirm your coverage.

Next storyMayo Clinic study finds blood test may predict Alzheimer's risk years in advance

All sections

Edition